AEM vs ERO

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

ERO presents a high-growth profile with a Piotroski F-Score of 4/9, indicating stable but not strong financial health. While the current price of $27.31 trades at a premium to the Graham Number ($22.61) and Intrinsic Value ($17.71), this is justified by explosive revenue growth (161.30% YoY) and a very attractive forward P/E of 6.17. The company exhibits exceptional profitability with an ROE of 34.91% and operating margins of 43.60%, significantly outperforming sector averages. Despite liquidity concerns reflected in a low quick ratio, the fundamental growth trajectory and analyst targets suggest continued upside.